Hemogenyx Pharmaceuticals Plc (LON:HEMO)

Hemogenyx Pharmaceuticals Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-11.31	-9.76	-5.62	-6.69	-3.98	-5.1
Depreciation & Amortization	0.52	0.59	0.64	0.65	0.2	0.13
Loss (Gain) From Sale of Assets	0	0	-	-	-	-
Asset Writedown & Restructuring Costs	-	0.27	-	-	-	-
Stock-Based Compensation	5.61	0.06	0.34	0.24	0.02	0.15
Other Operating Activities	3.63	4.64	-0.11	0.53	0.61	2.09
Change in Accounts Receivable	-0.13	-0.01	-0	0	-0	-0.2
Change in Accounts Payable	-0.24	0.43	0.35	0.03	-0.03	0.3
Change in Other Net Operating Assets	0.31	0.33	0.26	-0.87	0.27	-
Operating Cash Flow	-1.61	-3.45	-4.14	-6.11	-2.91	-2.63
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-	-0	-0.01	-0.12	-0.43	-0.64
Sale (Purchase) of Intangibles	-	-	-	-	-	-0.18
Other Investing Activities	0.02	-0	0.01	0.09	0.01	-0.12
Investing Cash Flow	0.02	-0.01	-0	-0.03	-0.42	-0.94

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Repaid	-	-0.63	-0.64	-0.64	-0.11	-3.22
Lease Payments	-0.61	-0.63	-0.64	-0.64	-0.11	-0.04
Net Debt Issued (Repaid)	-0.61	-0.63	-0.64	-0.64	-0.11	-3.22
Issuance of Common Stock	8.9	5.52	3.93	5.25	-	12
Other Financing Activities	-0.38	-	-0.21	-0.17	-	-
Financing Cash Flow	7.92	4.89	3.08	4.45	-0.11	8.78

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	-1.97	-0.01	-0.02	0.4	-0.88	-0.18
Miscellaneous Cash Flow Adjustments	-0	-	-	-	0.01	-
Net Cash Flow	4.36	1.43	-1.09	-1.29	-4.31	5.03

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	-1.61	-3.45	-4.15	-6.22	-3.34	-3.26
Free Cash Flow Growth	-	-	-	-	-	-
Free Cash Flow Per Share	-0.27	-0.78	-1.26	-2.20	-1.36	-1.69
Levered Free Cash Flow	-1.48	-3.33	-1.96	-4.37	-3.35	-3.11
Unlevered Free Cash Flow	-1.35	-3.19	-1.79	-4.18	-3.35	-2.24
Free Cash Flow After Leases	-2.21	-4.08	-4.79	-6.86	-3.45	-3.3

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Change in Working Capital	-0.06	0.75	0.6	-0.83	0.24	0.1

Data Source: S&P Global Market Intelligence Last updated: Sep 28, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 15, 2026

Data Sources Report a data error